Frequently Asked Questions
Projects can be designed to advance products in any of the four pillars of healthcare: medical devices, diagnostics, digital health, or therapeutics. i3 is not a funding mechanism to support basic research or generate results for grant applications.
MSIP is in charge of protecting and commercializing intellectual property (IP) that results from research conducted at Mount Sinai. Projects submitted to the i3 Asset Accelerator will be evaluated for commercial potential and MSIP will be involved so that any related IP is protected prior to public disclosure.
In contrast to traditional research grants, the i3 Asset Accelerator is exclusively focused on funding the development of commercial products. The experiments required to develop products are not typically emphasized in academic labs and are often the specialty of outside organizations such as CROs. In some cases, venture capital or industry representatives are more likely to partner with Mount Sinai to further research when key experiments are repeated outside of academic labs to verify the results. Experiments that de-risk a technology and make partnership more likely are ideal projects for the i3 Asset Accelerator.
Accelerator-funded projects will include “tranched” budgets, meaning the funding of later stages is contingent on successful completion of earlier phases and obtaining positive results. Milestones should be designed around steps that incrementally de-risk the technology and justify further investment that will continue to increase the value of the asset.
Yes, a proposal can have multiple PIs as long as they are all Mount Sinai faculty. No PI salaries will be supported by accelerator funds.